Related Experiment Video
Updated: Jul 18, 2026
16:26
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
Biologic immune modifiers: Trials and tribulations--are we there yet?
1Department of Pediatrics, Division of Allergy and Clinical Immunology, Women and Children's Hospital of Buffalo, State University of New York at Buffalo, School of Medicine and Biomedical Sciences, Buffalo, NY 14222, USA. ballow@buffalo.edu
The Journal of Allergy and Clinical Immunology
|December 13, 2006
Summary
New biologic agents, including monoclonal antibodies (mAbs) and recombinant proteins, offer promising therapeutic options for inflammatory allergic conditions like asthma. While research is ongoing, these immune modulators represent a future era in treating allergic disorders.
Area of Science:
- Immunology
- Pharmacology
- Allergy and Immunology
Background:
- Biologic agents represent a significant advancement in drug treatment.
- Immune response modulators, such as monoclonal antibodies (mAbs) and recombinant proteins, are key therapeutic modalities.
- Asthma serves as a model for understanding inflammatory allergic processes.
Purpose of the Study:
- To explore the use and potential of specific immune response modulators in asthma treatment.
- To provide a rationale for employing novel biologic agents in managing allergic diseases.
- To highlight the rapid advancement and future application of these therapies.
Main Methods:
- Focus on monoclonal antibodies (mAbs) and recombinant proteins as specific biologic agents.
- Review of current applications in animal models and other inflammatory/autoimmune diseases.
- Discussion of the rationale for their use in asthma.
Main Results:
- Biologic agents show high potential for treating inflammatory allergic processes like asthma.
- Current applications exist in animal models and other autoimmune diseases.
- Rapid advancements suggest future clinical application in allergic diseases.
Conclusions:
- Biologic agents are poised to revolutionize the treatment of allergic disorders.
- Caution is advised when extrapolating data from in vitro studies and animal models.
- Further understanding of immune and inflammatory processes will enhance therapeutic strategies.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...